Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cysteine-rich ocular surface mucin (None standardized; if referencing specific mucins, standard abbreviations are MUC1, MUC4, MUC16.)
- Target
- None standardized; if referencing specific mucins, standard abbreviations are MUC1, MUC4, MUC16.
- Molecular classification
- Other (Glycoprotein; specifically, membrane-associated mucins), Not a receptor, enzyme, channel, or transporter
01
Overview
Cysteine-rich ocular surface mucins refer to high molecular weight, heavily O-glycosylated membrane-associated glycoproteins, primarily MUC1, MUC4, and MUC16, expressed on the apical surface of corneal and conjunctival epithelia. These mucins form a dense, protective glycocalyx barrier critical for tear film stability, lubrication, and defense against mechanical, environmental, and microbial insults. Their cysteine-rich domains enable structural stability and cross-linking, enhancing barrier function. Disruption or alteration of these mucins is implicated in dry eye, ocular allergy, and other ocular surface pathologies.
- Other names
- Ocular surface mucinsMembrane-associated mucins (when referring to MUC1, MUC4, MUC16)Cell surface-associated mucins
02
Mechanism of action
Not applicable. These are not canonical drug targets; however, drugs designed to increase mucin production enhance lubrication and barrier properties.
03
Biological functions
Epithelial barrier formation and maintenanceSurface lubrication and tear film stabilityPrevention of adhesion (anti-adhesive function)Protection against pathogens and mechanical damageOsmosensing (hypothesized function)
04
Disease associations
Dry eye diseaseOcular allergyInfectious keratitisAutoimmune dry eye (Sjögren’s syndrome)Other ocular surface disorders
05
Safety considerations
Not drug targets; however, dysregulation or deficiency can lead to increased risk of ocular surface disease and infection
06
Interacting drugs
None directly. These mucins are not drug targets, but some drugs (artificial tears, mucin secretagogues) may affect their expression/function indirectly.
07
Biomarkers
Expression patterns of MUC1, MUC4, and MUC16 can serve as biomarkers of ocular surface health or disease status
Beyond the preview
Go deeper on Cysteine-rich ocular surface mucin (None standardized; if referencing specific mucins, standard abbreviations are MUC1, MUC4, MUC16.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cysteine-rich ocular surface mucin (None standardized; if referencing specific mucins, standard abbreviations are MUC1, MUC4, MUC16.).